International Clinical Trial: A prospective, single-arm, phase II clinical study of EGFR TKI combined with trastuzumab rezetecan for the first-line treatment of advanced NSCLC patients with EGFR mutations and HER2 gene variations or protein expression

Geneva, July 20 -- International Clinical Trials Registry received information related to the study (ChiCTR2600127858) titled 'A prospective, single-arm, phase II clinical study of EGFR TKI combined with trastuzumab rezetecan for the first-line treatment of advanced NSCLC patients with EGFR mutations and HER2 gene variations or protein expression' on July 8.

Study Type: Interventional study

Study Design: Single arm

Primary Sponsor: West China Hospital of Sichuan University

Condition: advanced NSCLC who have EGFR mutations combined with HER2 gene variations or protein expression

Recruitment Status: Not Recruiting

Phase: 2

Date of First Enrollment: 2026-07-08

Target Sample Size: EGFR-TKI combined with trastuzumab rezetecan:35; ...